



NEWS RELEASE

Biosensors to announce LEADERS FREE clinical results at TCT and host analyst briefing on 14 Oct 2015

Singapore, 12 October 2015 – Biosensors International Group, Ltd. (“**Biosensors**” or the “**Company**”, Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced that the Company will issue results of its LEADERS FREE clinical trial during the Transcatheter Cardiovascular Therapeutics (TCT) 2015 meeting Late Breaking Clinical Trials Session on 14 Oct 2015.

Conference Call Information

Biosensors’ management will also host an analyst conference call on 14 Oct 2015 at 6pm (San Francisco time) or 15 Oct 2015 at 9am (Singapore time). This briefing will allow the investment community to have a better understanding of the results. A live audio webcast of this analyst conference call will be available through Biosensors’ corporate website at www.biosensors.com on the day of the event.

###

Media/Investor Relations Contact

Tel: (65) 6213 5777

Email: ir@biosensors.com

About Biosensors International Group, Ltd

Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients’ lives through pioneering medical technology that pushes forward the boundaries of innovation. Founded in 1990, we were listed on the Mainboard of the Singapore Stock Exchange in 2005.

The Group currently operates through four business units (“BU”): the Cardiovascular BU, composed primarily of the BioMatrix™ & EXCEL families of drug-eluting stents, BioFreedom™ drug-coated stents and stent technologies such as BA9; the Cardiac Diagnostic BU, including Spectrum Dynamics products that offer advanced medical imaging and clinical solutions to help interventional cardiologists determine the most appropriate treatment for patients; the Peripheral Intervention BU, offering solutions for the treatment of patients with peripheral arterial disease; and the Critical Care Products BU.

The Group has operations worldwide and is headquartered in Singapore.

For more information, please visit www.biosensors.com.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.